Cooley Represents AcelRx Pharmaceuticals in Public Offering

Palo Alto, Calif. – July 25, 2013 – Cooley LLP announced today that it represented AcelRx Pharmaceuticals, Inc. in its public offering of approximately 4.8 million shares of common stock. AcelRx is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain. 

The offering closed on July 23, 2013.

Cooley represented AcelRx in its initial public offering in February 2011.

About Cooley LLP

Cooley's 700 attorneys have an entrepreneurial spirit and deep, substantive experience, and are committed to solving clients' most challenging legal matters. From small companies with big ideas to international enterprises with diverse legal needs, Cooley has the breadth of legal resources to enable companies of all sizes to seize opportunities in today's global marketplace. The firm represents clients across a broad array of dynamic industry sectors, including technology, life sciences, health care, venture capital, clean energy, real estate and retail.

The firm has full-service offices in eleven major business and technology centers: Boston, MA; Broomfield, CO; Los Angeles, CA; New York, NY; Palo Alto, CA; Reston, VA; San Diego, CA; San Francisco, CA; Seattle, WA; Washington, DC; and Shanghai, China.

Related Contacts
Scott Talbot Partner, Reston
Chadwick Mills Partner, San Francisco
Thomas Blinka Partner, Washington, DC
Natasha Leskovsek Partner, Washington, DC
Mark Weeks Partner, Palo Alto
Mark Windfeld-Hansen Partner, Palo Alto
Marina Remennik Special Counsel, Palo Alto
Andrew Keith Associate, Washington, DC